BioMarin Pharmaceutical Inc. cash flow to debt ratio of 128.80% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

BioMarin Pharmaceutical Inc.'s free cash flow has increased 52.49% from $475.42M last year to $724.96M, signaling increasing performance

BioMarin Pharmaceutical Inc.'s debt to equity ratio is 0.66, which means that the company's assets are unhealthy financed, signaling financial risk.

BioMarin Pharmaceutical Inc.'s debt has increased relative to shareholder equity from 0.11 last year to 0.66 today, signaling weakened financials

BioMarin Pharmaceutical Inc. has a net cash position, so leverage is healthy.

BioMarin Pharmaceutical Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BioMarin Pharmaceutical Inc.'s profit margin has decreased (85.68%) in the last year from 14.96% to 2.14%, signaling decreasing performance

BioMarin Pharmaceutical Inc.'s short-term assets of $3.95B exceed its short-term liabilities of $759.03M

BioMarin Pharmaceutical Inc.'s return on assets of 0.62% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioMarin Pharmaceutical Inc.'s return on equity of 1.18%, is lower than 15.00%, indicating bad performance

BioMarin Pharmaceutical Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

BioMarin Pharmaceutical Inc. had positive net income in 4 out of 5 years, indicating stable and consistent earnings

BioMarin Pharmaceutical Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

BioMarin Pharmaceutical Inc. has a free cash flow yield of 5.45%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

BioMarin Pharmaceutical Inc.'s yearly earnings has decreased 18.26% since last year from $426.86M to $348.90M, signaling decreasing performance

BioMarin Pharmaceutical Inc.'s yearly revenue has decreased 100.00% since last year from $2.85B to $0.00, signaling decreasing performance

ROIC 1.25% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioMarin Pharmaceutical Inc.'s 3-year revenue CAGR of 15.40% is positive, indicating growing revenue over the past 3 years

BioMarin Pharmaceutical Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

BioMarin Pharmaceutical Inc. had positive ROE in 4 out of 5 years, indicating consistent and reliable returns on equity

BioMarin Pharmaceutical Inc. has insufficient data to evaluate this check.

BioMarin Pharmaceutical Inc. has an earnings yield of 0.55%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

BioMarin Pharmaceutical Inc. is overvalued relative to its fair value price of 24.34 based on EBITDA multiple model

BioMarin Pharmaceutical Inc. has an EV/EBITDA ratio of 21.64x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

BioMarin Pharmaceutical Inc. is overvalued relative to its fair value price of 25.33 based on Earnings Fair Value model

BioMarin Pharmaceutical Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

BioMarin Pharmaceutical Inc. has a price-to-book ratio of 2.10x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioMarin Pharmaceutical Inc. has a price-to-sales ratio of 3.90x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue